ライフサイエンスコーパス: gastrointestinal symptom

1 eady been demonstrated by cardiovascular and gastrointestinal symptoms.

2 y scores had a positive correlation with all gastrointestinal symptoms.

3 spital because of dehydration and persistent gastrointestinal symptoms.

4 uch as ataxia or neuropathy, with or without gastrointestinal symptoms.

5 ossible COVID-19 in patients presenting with gastrointestinal symptoms.

6 , even in mild disease and in the absence of gastrointestinal symptoms.

7 ode of PPOI characterized by upper and lower gastrointestinal symptoms.

8 infusions of the tastants did not result in gastrointestinal symptoms.

9 ortant role in assessing patients with upper gastrointestinal symptoms.

10 treatment resistant, upper or lower chronic gastrointestinal symptoms.

11 adverse events were headache, asthenia, and gastrointestinal symptoms.

12 291746) had frequent (>/= 3 days/week) upper gastrointestinal symptoms.

13 f D. fragilis positive children with chronic gastrointestinal symptoms.

14 ffects in the antibiotic group, particularly gastrointestinal symptoms.

15 ned by a combination of chronic or recurrent gastrointestinal symptoms.

16 ow in FODMAPs effectively reduced functional gastrointestinal symptoms.

17 entations were fever, weakness, myalgia, and gastrointestinal symptoms.

18 considered in pediatric patients with upper gastrointestinal symptoms.

19 lated adverse events were largely limited to gastrointestinal symptoms.

20 , flushing, tachycardia and headache but not gastrointestinal symptoms.

21 sociated with decreased HRQOL and persistent gastrointestinal symptoms.

22 with non-IgE-mediated cow's milk allergy and gastrointestinal symptoms.

23 The acute phase is characterized by gastrointestinal symptoms.

24 ated with marked peripheral eosinophilia and gastrointestinal symptoms.

25 verse event, followed by fatigue, edema, and gastrointestinal symptoms.

26 eadache, confusion, and neuropsychiatric and gastrointestinal symptoms.

27 ool specimens (n = 79) from 77 patients with gastrointestinal symptoms.

28 dications commonly caused withdrawals due to gastrointestinal symptoms.

29 gnostic possibility for patients with common gastrointestinal symptoms.

30 e varied, half of the patients initially had gastrointestinal symptoms.

31 yed gastric emptying by scintigraphy without gastrointestinal symptoms.

32 T regulatory CD4+ cells, and amelioration of gastrointestinal symptoms.

33 atory bowel disorder that is associated with gastrointestinal symptoms.

34 malabsorption is associated with unexplained gastrointestinal symptoms.

35 een-found patients tend to have little or no gastrointestinal symptoms.

36 e been reported in children with and without gastrointestinal symptoms.

37 : 9.4% [95% CI 6.6-12.2]), partly because of gastrointestinal symptoms.

38 Celiac disease causes a wide range of gastrointestinal symptoms.

39 a breath test and could not be predicted by gastrointestinal symptoms.

40 ed less than 1 week after onset of fever and gastrointestinal symptoms.

41 recurs unpredictably and can lead to chronic gastrointestinal symptoms.

42 with respiratory symptoms, and 54 (90%) with gastrointestinal symptoms.

43 ue to mutations in TYMP, often presents with gastrointestinal symptoms.

44 th severe lung injury and constitutional and gastrointestinal symptoms.

45 acaftor treatment, patient reported improved gastrointestinal symptoms.

46 nflammation, perturbed neural circuitry, and gastrointestinal symptoms.

47 e, with the most common adverse events being gastrointestinal symptoms.

48 ota composition, microbial fermentation, and gastrointestinal symptoms.

49 d 20% of patients with COVID-19 present with gastrointestinal symptoms.

50 hereas Glx was unrelated to psychological or gastrointestinal symptoms.

51 ars or diagnosed with CMA with predominantly gastrointestinal symptoms.

52 ing to absence of gut innervation and severe gastrointestinal symptoms.

53 (10% of the overall group) due to persistent gastrointestinal symptoms.

54 nced systemic reactions, and 49% experienced gastrointestinal symptoms.

55 time, and the severity of psychological and gastrointestinal symptoms.

56 ollow-up, in pediatric patients with chronic gastrointestinal symptoms.

57 ts discontinued the study, mostly because of gastrointestinal symptoms.

58 noncases were less likely than cases to have gastrointestinal symptoms.

59 es were used to measure hunger, satiety, and gastrointestinal symptoms.

60 Gastrointestinal symptoms (0.88 [0.85-0.91]) made probab

61 polyps or cancer (30.1%), bleeding (31.2%), gastrointestinal symptoms (11.8%), or a positive result

62 the meat after returning home and developed gastrointestinal symptoms 2 days later.

63 s for discontinuation were inefficacy (30%), gastrointestinal symptoms (29%), medication noncomplianc

64 ad eschar, 29% had lymphadenopathy, 100% had gastrointestinal symptoms, 34% had neurologic symptoms,

65 Five of 12 had gastrointestinal symptoms (42%).

66 77), and 4.9% in the remaining patients with gastrointestinal symptoms (55/1122).

67 ever or chills; 97% had tachycardia, 80% had gastrointestinal symptoms, 60% had rash, 56% had conjunc

68 s presented with respiratory symptoms (97%), gastrointestinal symptoms (77%), and constitutional symp

69 a sure diagnosis of non-IgE-mediated CMA and gastrointestinal symptoms (97 boys, 56.4%; age, 6.37 m;

70 Nemolizumab was associated with gastrointestinal symptoms (abdominal pain and diarrhea)

71 analogue scales assessing the severity of 5 gastrointestinal symptoms (abdominal pain, bloating, nau

72 We defined CFP case-patients as persons with gastrointestinal symptoms (abdominal pain, vomiting, dia

73 Chronic gastrointestinal symptoms after pelvic radiotherapy are

74 Gastrointestinal symptoms after pelvic radiotherapy, whi

75 f applied appropriately to patients with new gastrointestinal symptoms after radiotherapy, can identi

76 V-HD had gastroenteritis, and 1 had multiple gastrointestinal symptoms; all recovered.

77 estinal symptoms, followed by respiratory or gastrointestinal symptoms alone; the best outcomes were

78 Leukopenia, thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were th

79 s, neutralizing anti-IL-17 or -IL-22 Abs, or gastrointestinal symptoms, although scarcity of the avai

80 lly associated with a spike in self-reported gastrointestinal symptoms among staff.

81 o immunoconverted, 40% reported at least one gastrointestinal symptom and 33% reported diarrhea, comp

82 8/9 had non specific upper gastrointestinal symptoms and 3/9 had rectocolic inflamm

83 cline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or

84 e describe a kindred with slowly progressive gastrointestinal symptoms and autonomic neuropathy cause

85 Norovirus shedding was associated with gastrointestinal symptoms and concomitant viremia in 54.

86 An association between gastrointestinal symptoms and contact with floodwater wa

87 neuromodulators in the treatment of chronic gastrointestinal symptoms and FGIDs.

88 The presence of gastrointestinal symptoms and high levels of viral RNA i

89 gnificantly decreased vomiting frequency and gastrointestinal symptoms and improved quality of life i

90 tool colonization in 29% of patients without gastrointestinal symptoms and in 55% of patients with pr

91 is typically based on clinical presentation (gastrointestinal symptoms and inflammation) and the dete

92 MNGIE mainly presents with gastrointestinal symptoms and is mostly misdiagnosed in

93 re acceptable than AA-MFs and noted improved gastrointestinal symptoms and less hunger with GMP-MFs.

94 The impact of esophagectomy on gastrointestinal symptoms and long-term HRQOL should be

95 extremely variable; patients may have severe gastrointestinal symptoms and malabsorption, extraintest

96 ried clinical signs including, among others, gastrointestinal symptoms and neuropsychiatric manifesta

97 se who immunoconverted, 10% reported chronic gastrointestinal symptoms and none experienced diarrhea.

98 e the long-term outcome of gastric emptying, gastrointestinal symptoms and nutritional status after l

99 The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were meas

100 in the presence of gastrointestinal and non-gastrointestinal symptoms and overlap syndromes.

101 agents were commonly associated with adverse gastrointestinal symptoms and poor palatability.

102 Patients with APECED frequently have gastrointestinal symptoms and seroreactivity against sec

103 ore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulcer, particular

104 recurrence), the presence and recurrence of gastrointestinal symptoms and the length of hospital sta

105 Validated questionnaires were used to assess gastrointestinal symptoms and the modified body mass ind

106 n healthy volunteers on hunger, satiety, and gastrointestinal symptoms and the release of GLP-1 and P

107 tionnaires to describe the onset and type of gastrointestinal symptoms and treatment they had before

108 The high frequency of gastrointestinal symptoms and weight loss mirrors result

109 GE was remarkably common and associated with gastrointestinal symptoms and with measures of early and

110 flushing, tachycardia, and headache, but not gastrointestinal symptoms), and reduction in itching and

111 Three patients (21%) experienced gastrointestinal symptoms, and 1 (7%) discontinued the u

112 children had respiratory complaints, 30% had gastrointestinal symptoms, and 63% of children with thes

113 related to syncope, respiratory symptoms, or gastrointestinal symptoms, and a physician was frequentl

114 ients with the disease might have mainly non-gastrointestinal symptoms, and as a result patients pres

115 observed toxicity included myelosuppression, gastrointestinal symptoms, and asymptomatic hyperbilirub

116 umami) on food intake, hunger and fullness, gastrointestinal symptoms, and gastrointestinal peptide

117 ctors, nutritional outcomes, adverse events, gastrointestinal symptoms, and health-related quality of

118 reases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.

119 increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.

120 e and included respiratory tract infections, gastrointestinal symptoms, and hypertension.

121 vents with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver

122 MPS withheld/discontinued due to leukopenia, gastrointestinal symptoms, and infection were 12 of 100,

123 depleted plasma concentrations of serotonin, gastrointestinal symptoms, and motor-sensory function in

124 h), abnormal pupillary light response, upper gastrointestinal symptoms, and neurogenic bladder.

125 status, use of opioids, blood transfusions, gastrointestinal symptoms, and sleep disturbance items,

126 associated with the development of new-onset gastrointestinal symptoms, and the presence of gastroint

127 t (29%) had lymphadenopathy, eight (29%) had gastrointestinal symptoms, and three (11%) had stiff nec

128 Carbohydrate malabsorption and subsequent gastrointestinal symptoms are a common clinical problem

129 Although gastrointestinal symptoms are common after the acute pha

130 Gastrointestinal symptoms are common in children with au

131 s well described in long-term follow-up, and gastrointestinal symptoms are common, data on gut and pa

132 New gastrointestinal symptoms are frequent after pelvic radi

133 Gastrointestinal symptoms are highly prevalent, but many

134 to base a confident conclusion as to whether gastrointestinal symptoms are more common in children wi

135 Nausea and gastrointestinal symptoms are the chief tolerability iss

136 Persistent fever and gastrointestinal symptoms are the most common symptoms.

137 vidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do

138 t tolerated oral miltefosine well, with mild gastrointestinal symptoms as the most common systemic si

139 tives included patients' assessment of their gastrointestinal symptoms as well as treatment safety an

140 associated with a wide variety of individual gastrointestinal symptoms, as well as headaches, fatigue

141 1) concentrations, appetite perceptions, and gastrointestinal symptoms at 15-min intervals.

142 ta from 1848 consecutive adult patients with gastrointestinal symptoms at 2 hospitals in Hamilton, On

143 Children presenting with gastrointestinal symptoms at the Royal Hospital for Sick

144 ending on different assumptions, the cost of gastrointestinal symptoms attributable to water recreati

145 ic survey asked detailed questions regarding gastrointestinal symptoms before and after the instituti

146 Tap water consumption was not related to gastrointestinal symptoms before, during, or after the f

147 The drug was well tolerated, with gastrointestinal symptoms being the most common complain

148 ples collected from neonates with or without gastrointestinal symptoms between 1999 and 2000 were gen

149 ed mycophenolate sodium (EC-MPS) in terms of gastrointestinal symptom burden has been evaluated previ

150 Change in gastrointestinal symptom burden was evaluated using a va

151 itis) and typically developing children with gastrointestinal symptoms but no evidence of gastrointes

152 f children with non-IgE-mediated CMA-related gastrointestinal symptoms by contributing in determining

153 SFTS disease is characterized by gastrointestinal symptoms, chills, joint pain, myalgia,

154 shing and pruritus, dysautonomia, functional gastrointestinal symptoms, chronic pain, and connective

155 placebo 24.3%), and they were predominantly gastrointestinal symptoms (colchicine, 23.0% versus plac

156 The questionnaire included gastrointestinal symptoms commonly reported to be associ

157 ee diet associated with small improvement in gastrointestinal symptoms compared with no gluten-free d

158 A total of 2334 patients with gastrointestinal symptoms composed the study group, whic

159 th few side effects, including headaches and gastrointestinal symptoms, concerns are raised regarding

160 In all participants, gastrointestinal symptoms consistently and significantly

161 Reported worldwide as causing human gastrointestinal symptoms, D. fragilis is very common an

162 Reported gastrointestinal symptoms did not differ significantly b

163 d age, gender, body mass index, and baseline gastrointestinal symptoms did not predict whether celiac

164 CVID patients with gastrointestinal symptoms differed from asymptomatic CVI

165 be considered in future cases of persistent gastrointestinal symptoms during food allergy immunother

166 An increase in the incidence of gastrointestinal symptoms during the flood was observed

167 medical conditions that themselves result in gastrointestinal symptoms (e.g., inflammatory bowel dise

168 he subset of PPOI patients who display lower gastrointestinal symptoms exclusively after surgery.

169 The surveys measured gastrointestinal symptoms experienced during the past ye

170 nts presenting with combined respiratory and gastrointestinal symptoms, followed by respiratory or ga

171 Over two-thirds of patients with upper gastrointestinal symptoms following RYGB will have one o

172 study of patients (>/=18 years) with chronic gastrointestinal symptoms for 12 months or more after ra

173 logical, and genetic factors associated with gastrointestinal symptoms for patients with mastocytosis

174 ecal specimens from 62 Kuwaiti children with gastrointestinal symptoms found to be positive by micros

175 glia could, to a certain extent, explain the gastrointestinal symptoms frequently experienced by CF p

176 effect of sex on gastric emptying, appetite, gastrointestinal symptoms, glucose, or gut hormones (P >

177 Since November 2000, coincidentally, data on gastrointestinal symptoms had been collected for a drink

178 nificant proportion of children with ASD and gastrointestinal symptoms have histologic evidence of il

179 factors, pulmonary function, vitamin status, gastrointestinal symptoms, health-related quality of lif

180 d improvement in neuropathic pain, sweating, gastrointestinal symptoms, hearing loss, and pulmonary s

181 ute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperg

182 NHPGHs) are associated with a range of upper gastrointestinal symptoms, histologic and endoscopic fin

183 thy individuals and frequently manifest with gastrointestinal symptoms; however, their ability to cau

184 ociated antibodies decreased (P < .003), and gastrointestinal symptoms improved to a greater extent t

185 (87%), shortness of breath in 11 (48%), and gastrointestinal symptoms in 8 (35%); 20 patients (87%)

186 examined the effect of a gluten-free diet on gastrointestinal symptoms in a cohort of US patients wit

187 e the first report of an increase in endemic gastrointestinal symptoms in a longitudinal cohort prosp

188 c inflammatory bowel disease associated with gastrointestinal symptoms in CVID is a unique combinatio

189 ties are associated with increased levels of gastrointestinal symptoms in general.

190 (FODMAPs) often is used to manage functional gastrointestinal symptoms in patients with irritable bow

191 t in an increase in the endemic incidence of gastrointestinal symptoms in the United States.

192 % of the infections were in children who had gastrointestinal symptoms, including acute watery diarrh

193 of enteric infections, we observed long-term gastrointestinal symptoms, including reduced motility an

194 that patients with radiation-induced chronic gastrointestinal symptoms, including those patients with

195 in adults, the pediatric model also included gastrointestinal symptoms (inverse association), and the

196 Lactose intolerance resulting in gastrointestinal symptoms is a common health concern.

197 strointestinal symptoms, and the presence of gastrointestinal symptoms is associated with the develop

198 t COVID-19 in patients presenting with acute gastrointestinal symptoms is extremely low with an addit

199 ffected individuals suffered with prevailing gastrointestinal symptoms leading to the diagnosis of AL

200 Gastrointestinal symptoms limited adherence.

201 In rare cases this can result in atypical gastrointestinal symptoms, making the diagnosis of Nutcr

202 mall intestinal microbiomes in patients with gastrointestinal symptoms may allow a more targeted anti

203 mmunosuppressive regimen with posttransplant gastrointestinal symptoms may benefit from a conversion

204 Primary outcome was change in level of gastrointestinal symptoms, measured on a visual-analog-s

205 Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n =

206 maturely discontinued treatment due to ECMPS gastrointestinal symptoms (n=2), skin intolerance to APM

207 Most common adverse events included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%],

208 ssess relationships between nausea and other gastrointestinal symptoms, non-gastrointestinal somatic

209 However, the frequency of gastrointestinal symptoms observed in population-based s

210 Minimal gastrointestinal symptoms occurred during the trial.

211 The following gastrointestinal symptoms occurred more frequently and w

212 Gastrointestinal symptoms occurred more often with whey

213 rotoxin (CPE) is responsible for causing the gastrointestinal symptoms of C. perfringens type A food

214 Medical history and gastrointestinal symptoms of patients with mastocytosis

215 are not involved in the pathogenesis or the gastrointestinal symptoms of PD.

216 ium perfringens enterotoxin (CPE) causes the gastrointestinal symptoms of the second most common bact

217 ms began a median of 10.5 days after initial gastrointestinal symptoms, often accompanied by fever (n

218 ents with SEP-363856 included somnolence and gastrointestinal symptoms; one sudden cardiac death occu

219 et set criteria (presenting with skin and/or gastrointestinal symptoms only and skin prick test < 8 m

220 Patients without any gastrointestinal symptoms or disease (n = 192) composed

221 iduals for at least 6 months without causing gastrointestinal symptoms or impacting the composition o

222 Prebiotics do not improve gastrointestinal symptoms or QoL in patients with IBS or

223 was 15% or less, and the tests used included gastrointestinal symptoms or serum antibody tests.

224 aving isolated nonallergic symptoms, such as gastrointestinal symptoms, or patients solely with a fam

225 e); 2) non-classical (extraintestinal and/or gastrointestinal symptoms other than diarrhea); 3) subcl

226 .05) but also resulted in an increase in the gastrointestinal symptoms pain (P-treatment x time inter

227 ) from clinics in London, UK, with new-onset gastrointestinal symptoms persisting 6 months after pelv

228 en's race/ethnicity but not their associated gastrointestinal symptoms predicted whether celiac testi

229 Assessment of gastrointestinal symptoms, psychological traits, and dai

230 cs compared with placebo on global response, gastrointestinal symptoms, quality of life (QoL), and gu

231 Events for which the gastrointestinal symptom questionnaire was most discrimi

232 the validated Reflux Symptom Score (RSS) and Gastrointestinal Symptom Rating Scale (GSRS) questionnai

233 The Gastrointestinal Symptom Rating Scale (GSRS) was complet

234 ocyte density; clinical symptoms measured by gastrointestinal symptom rating scale (GSRS), coeliac di

235 weeks postbaseline), patients completed the Gastrointestinal Symptom Rating Scale (GSRS), Gastrointe

236 mptom burden was evaluated using a validated Gastrointestinal Symptom Rating Scale (GSRS).

237 ding the Bristol stool form scale (BSFS) and gastrointestinal symptom rating scale (GSRS).

238 ionwide study, 596 patients filled validated Gastrointestinal Symptom Rating Scale and Psychological

239 Therefore, this study aimed to translate the Gastrointestinal Symptom Rating Scale for Irritable Bowe

240 had a significantly greater decrease in the Gastrointestinal Symptom Rating Scale indigestion syndro

241 Symptoms were measured by Gastrointestinal Symptom Rating Scale Irritable Bowel Sy

242 The indigestion subscore of the Gastrointestinal Symptom Rating Scale questionnaire (GSR

243 A modified Gastrointestinal Symptom Rating Scale questionnaire was

244 The Gastrointestinal Symptom Rating Scale Reflux dimension w

245 outcome was a change from baseline in total Gastrointestinal Symptom Rating Scale score of a minimal

246 rence in average on-treatment Celiac Disease Gastrointestinal Symptom Rating Scale score.

247 symptoms, as expressed by the change in the Gastrointestinal Symptom Rating Scale scores (1.7+/-0.3

248 After comparing changes in Gastrointestinal Symptom Rating Scale total scores and s

249 symptoms were assessed (using the validated gastrointestinal symptom rating scale) before and after

250 parameters, and tolerability as rated by the Gastrointestinal Symptom Rating Scale.

251 Faecal calprotectin (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel S

252 , MMF-treated renal transplant patients with gastrointestinal symptoms receiving cyclosporine or tacr

253 irus infection, with relatively high rate of gastrointestinal symptoms reported.

254 in patients presenting with primarily acute gastrointestinal symptoms requiring abdominal imaging.

255 ubset of patients have developed significant gastrointestinal symptoms requiring discontinuation of t

256 The patient reported a lifetime of gastrointestinal symptoms requiring over 20 hospitalizat

257 The Gastrointestinal Symptom Response Scale was completed we

258 s the change in symptoms using the validated Gastrointestinal Symptom Score (GIS(c)).

259 thy (P = .05), and a greater composite upper gastrointestinal symptom score (P < .05).

260 Subjects with IBS had lower overall gastrointestinal symptom scores (22.8; 95% confidence in

261 vine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL

262 Gastrointestinal symptom scores for diarrhea (P = 0.0298

263 on for hereditary ATTR amyloidosis, although gastrointestinal symptom scores had increased over time.

264 ip between these variables and the course of gastrointestinal symptom scores over time was analyzed u

265 Gastrointestinal symptom scores were computed using Euro

266 Gastrointestinal symptom scores, however, had increased

267 depth, serology and laboratory test results, gastrointestinal symptom scores, physiologic well-being,

268 baseline to 12-month follow-up decreases in gastrointestinal symptom severity (estimated mean differ

269 dy assessing symptoms (Patient Assessment of Gastrointestinal Symptom Severity Index), duodenal alter

270 h placebo, relamorelin did not improve other gastrointestinal symptoms, such as abdominal pain and sa

271 also associated with increased prevalence of gastrointestinal symptoms, suggesting that the Na(+) cha

272 better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual

273 The gastrointestinal symptoms that followed the first intrad

274 associated with decreased HRQOL and lasting gastrointestinal symptoms up to 20 years after surgery.

275 Secondary outcomes were gastrointestinal symptoms, waist circumference, glycemic

276 Other than pain, the most common reported gastrointestinal symptom was nausea (86 %).

277 nt of rCDI (n=31), as well as development of gastrointestinal symptoms was assessed.

278 Pneumonia without gastrointestinal symptoms was associated with a 36.3% mo

279 increased susceptibility to colon cancer and gastrointestinal symptoms, we aimed to identify rhythmic

280 l, children aged 3-12 years with >4 weeks of gastrointestinal symptoms were allocated using block ran

281 e years after liver transplantation, whereas gastrointestinal symptoms were assessed in median nine m

282 Injection site reactions and gastrointestinal symptoms were common adverse events in

283 hemoglobin (HbA1c), complications of DM, and gastrointestinal symptoms were evaluated.

284 on, blood glucose, appetite perceptions, and gastrointestinal symptoms were measured during 90-min in

285 Gastrointestinal symptoms were more common with folic ac

286 Gastrointestinal symptoms were present in only 13%.

287 Gastrointestinal symptoms were prominent.

288 Patients with chronic upper gastrointestinal symptoms were prospectively evaluated.

289 physical functioning, and more vasomotor and gastrointestinal symptoms were significant risk factors

290 Among tolerability measures, gastrointestinal symptoms were significantly greater in

291 Gastrointestinal symptoms were significantly more preval

292 Gastrointestinal symptoms were the most common adverse e

293 Some gastrointestinal symptoms were worse in patients treated

294 Gastrointestinal symptoms were, collectively, most commo

295 rCDI (n = 31), as well as the development of gastrointestinal symptoms, were assessed.

296 Medical symptoms, particularly gastrointestinal symptoms, were common.

297 dy, the most common adverse events were mild gastrointestinal symptoms, which were seen in 90 of 120

298 patients presenting with acute non-traumatic gastrointestinal symptoms, who underwent standardized co

299 The patient had worsened gastrointestinal symptoms with mycophenolate mofetil or

300 36.3% mortality (respiratory phenotype), and gastrointestinal symptoms without pneumonia with a 5.3%